Federal Lawsuit Challenges FDA's Refusal to Allow Dietary Supplement Disease-Risk Claims

A lawsuit filed in the US District Court for the District of Columbia is challenging the FDA’s denial of a petition seeking authorization for more than 100 nutrient-disease risk-reduction health claims for dietary supplements. The case, Alliance for Natural Health USA et al. v. United States Department of Health and Human Services et al., was filed in January 2026 after the agency rejected the petition the previous December.¹

According to Claudia Lewis, co-chair of Venable LLP’s FDA Group, and Alexander Rubel, an associate with the firm, the case carries substantial commercial stakes: if the plaintiffs prevail, the range of claims available to both dietary supplements and conventional foods would expand significantly.

The petition, compiled by the Alliance for Natural Health USA along with several dietary supplement companies, proposed claims including "Riboflavin may reduce the risk of migraine headaches" and "Chromium may reduce the risk of type 2 diabetes," all drawn, according to the plaintiffs, directly from statements published on the websites of the National Institutes of Health and the Centers for Disease Control and Prevention (CDC).²

What Legal Pathway Is at the Center of This Dietary Supplement Health Claims Case?

Health claims for foods and dietary supplements generally require premarket authorization from the FDA. The traditional route requires petitioners to demonstrate "significant scientific agreement" among qualified experts that a claim is accurate, a standard that requires the agency to engage in formal rulemaking before authorizing the claim. This is a process that as Lewis and Rubel note, has historically proven difficult to satisfy and slow to complete.

A second, faster pathway was created by the Food and Drug Administration Modernization Act of 1997. Under this "authoritative statement" pathway, a petitioner can bypass both the significant scientific agreement standard and the rulemaking requirement by showing that a federal scientific body with official responsibility for public health, such as the National Institutes of Health or the Centers for Disease Control and Prevention, or the National Academy of Sciences, has published a currently effective authoritative statement identifying the relevant nutrient level.

FDA’s longstanding position is that this pathway applies only to conventional foods, not dietary supplements, an interpretation the new complaint directly challenges, arguing that the statute does not draw that distinction.¹

How Does This Case Relate to Prior First Amendment Challenges Against the FDA?

The Alliance for Natural Health USA is not new to this type of litigation. Its predecessor organization was a co-plaintiff in Pearson v. Shalala, a 1999 decision from the US Court of Appeals for the District of Columbia Circuit that found FDA’s health claims framework unconstitutional under the First Amendment in certain respects.³

That decision held that the agency could not reject health claims it found merely "potentially misleading" without first considering whether a clarifying disclaimer could resolve the concern, and separately found the agency's undefined "significant scientific agreement" standard arbitrary and capricious under the Administrative Procedure Act. A related follow-on case in 2001 again found in the plaintiffs' favor regarding a folic acid and neural tube defect claim.

The new complaint draws on this same line of argument but is built on a different statutory provision, which is the authoritative statement pathway rather than the significant scientific agreement standard at issue in Pearson. The plaintiffs argue that FDA’s narrow interpretation of "authoritative" amounts to suppressing accurate, government-sourced information without the kind of empirical justification First Amendment commercial speech doctrine requires.

What Is the Current Regulatory and Public Health Context for This Dispute?

The plaintiffs frame their case partly around the scale of chronic disease in the United States, citing CDC data indicating that roughly three-quarters of US adults have at least one chronic condition, a figure that rises substantially among adults over 65.² The case also arrives amid broader policy attention to nutrition and chronic disease prevention at the federal level.

For finished product manufacturers, the case is being closely watched because its outcome would directly affect what disease-risk language can appear on product labeling without the rulemaking process currently required under the significant scientific agreement standard.

References

1. Lewis CA, Rubel AS. New complaint challenges FDA's denial of dietary supplement health claims. Venable LLP Insights. June 11, 2026. Accessed June 17, 2026. https://www.venable.com/insights/publications/2026/06/new-complaint-challenges-fdas-denial-of-dietary

2. Alliance for Natural Health USA. ANH sues FDA: Standing up for your right to know. January 22, 2026. Accessed June 17, 2026. https://anh-usa.org/anh-sues-fda-standing-up-for-your-right-to-know/

3. Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999).